Latest Financial Health News

Telstra Group Limited has announced an additional $1 billion on-market share buy-back following a recent $750 million program, underscoring its strong financial position and commitment to shareholder returns.

Westpac Banking Corporation reported a robust 14% increase in statutory net profit for 3Q25, supported by disciplined growth and resilient credit quality. The bank’s capital and liquidity metrics remain comfortably above regulatory requirements, underscoring its financial strength.

Vista Group International reports robust H1 2025 results with strong revenue growth and margin expansion, driven by accelerating client adoption of its Vista Cloud platform and a new Embedded Payments initiative.

Northern Star Resources will unveil its FY25 financial results on 21 August, accompanied by a live conference call featuring key executives. Investors await insights into the gold miner’s performance and strategic outlook.

Evolution Mining Limited has announced a fully franked ordinary dividend of AUD 0.13 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan offering a 5% discount.

Evolution Mining has delivered a landmark FY25 with record profits and cash flow, tripling its final dividend, while setting a stable production and cost outlook for FY26 amid ongoing project developments and sustainability commitments.

Amotiv Limited has announced a fully franked ordinary dividend of AUD 0.22 per share for the financial year ending June 2025, payable in September. The dividend reflects the company’s steady financial position and commitment to shareholder returns.

Treasury Wine Estates has announced a fully franked ordinary dividend of AUD 0.20 per share for the six months ending June 2025, with a Dividend Reinvestment Plan available to shareholders.

Nutritional Growth Solutions Ltd has clarified discrepancies in its June 2025 quarterly reports, attributing changes to timing and classification adjustments, while reaffirming its financial health and governance compliance.

Platinum Asia Investments Limited has announced a special dividend of AUD 0.1992 per share, pending court approval and final confirmation post-scheme valuation. The payment is scheduled for September 2025 with a significant franked component.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

Scentre Group has announced an ordinary dividend of AUD 0.08815 per security for the half-year ended 30 June 2025, payable on 29 August. The dividend is fully unfranked and includes a Dividend Reinvestment Plan with no discount.